anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Congenital esotropia is the most common form of childhood strabismus. Despite its common occurrence, limited information is available about its early clinical course. Such data are needed to determine the earliest age at which surgery can be safely performed without concern that the esotropia is likely to resolve spontaneously. Although the term congenital esotropia implies that the esotropia is present at birth, in many cases the esotropia actually develops sometime during the first few months of life. It is well recognized that congenital esotropia persisting through 6 months of age rarely if ever resolves spontaneously and therefore requires surgical correction. However, it is not clear how often congenital esotropia occurs and then resolves (at an earlier age such that surgery is not necessary) before surgery is required.

Current clinical practice is to defer surgery for congenital esotropia until 6 to 12 months of age. Assuming that characteristics of congenital esotropia at 2 to 4 months of age can be identified to predict which cases will require surgery, then a trial will be warranted to determine whether performing earlier surgery enhances the development of binocular vision. The potential benefit to very early surgery is supported by neurophysiologic research, which has shown that (1) congenital esotropes may be born with the innate ability to develop binocular vision, (2) there is a critical period for development of normal binocular function within the first few months of life that is dependent on alignment of the visual axes of the two eyes, and (3) ocular misalignment alone, regardless of its mechanism, without a coexisting primary cortical fusion deficit, can account for abnormal development of binocular vision. Clinical reports have demonstrated that surgical correction of the esotropia between 6 and 12 months of age provides for enhanced development of stereoacuity compared with later surgery. However, there are limited data on the outcomes in infants who had surgical correction before age 6 months.

The protocol for the study is identical to usual clinical practice. Following informed consent, two followup visits are conducted: one 2 to 4 weeks after the first examination and the other when the child is between 28 and 32 weeks of age. The examinations will be identical to the pediatric ophthalmologist's usual routine, and no additional procedures are being performed specifically for the study. Management of refractive error and amblyopia is left to the ophthalmologist's discretion. A sample size of 150 has been projected for the study.
An object of the present invention is to provide a remedy for dysfunction of central monoamine pathway, a method for screening a PTP.zeta. inhibitor or activator, which is useful as a remedy for gastric ulcer caused by Helicobacter pylori or pleiotrophin which is a heparin-binding secretory protein, and a non-human model animal being hyposensitive to a stimulant drug, VacA which is a toxin of Helicobacter pylori, or pleiotrophin by utilizing the physiological function of PTP.zeta.. After administering a subject material to PTP.zeta. knockout mice and wild-type mice, PTP.zeta. activity in the PTP.zeta. knockout mice and the wild-type mice is compared and evaluated to screen a PTP.zeta. inhibitor or activator. Examples of the comparison and the evaluation of the PTP.zeta. activity include the comparison and the evaluation of the function of central monoamine pathway such as changes in the level of central monoamine metabolism, sensitivity to a stimulant drug, the presence of dysfunction of mesolimbic dopamine pathway, level of acclimation to new circumstances, or stress-responsiveness, and the comparison and the evaluation of the level of binding to VacA, a toxin of Helicobacter pylori, or pleiotrophin.
PURPOSE: Provided are halophile microorganism Bacillus subtilis BS-4 capable of producing high molecular weight of poly-γ-glutamic acid and a method for producing the high molecular weight of poly-γ-glutamic acid using the same, thereby producing the high molecular weight poly-γ-glutamic acid in higher yield. CONSTITUTION: The halophile microorganism Bacillus subtilis BS-4 (KCTC 0697BP) capable of producing high molecular weight of poly-γ-glutamic acid is isolated from 'Chug Kook Jang'(Fermented soybean paste) by the steps of: diluting 'Chug Kook Jang' in distilled water; heating the diluted solution at 60 deg. C for 20 minutes; plating the diluted solution on GS agar medium; culturing it at 37 deg. C for 3 days; isolating high viscosity of colonies; culturing the colonies in a broth at 37 deg. C for 20 hours; and selecting a strain showing the best growth activity. The method for producing the high molecular weight of poly-γ-glutamic acid comprises the steps of: (a) culturing the Bacillus subtilis BS-4(KCTC 0697BP) to obtain poly-γ-glutamic acid; and (b) removing polysaccharides from the poly-γ-glutamic acid; dissolving the precipitate of poly-γ -glutamic acid and adding a protease into the solution to decompose an extracellular protein; and dialyzing the solution to remove free glutamic acid and concentrating the solution.
Autism Spectrum Disorder (ASD) is a lifelong neurodevelopmental disability with increasing prevalence worldwide. Its symptoms include limitations in social interaction and repetitive and restrictive behaviors. These symptoms may result in difficulties in participating in daily life and social activities across the lifespan. The main challenges include poor communication, social interaction, and emotional regulation skills that can limit and impair a person's everyday functioning. Many parents of children with ASD had an increased caregiver burden. In addition, the total lifetime cost of autism per individual is about 3.6 million US dollars. Thus, there is an urgent need to develop appropriate and effective interventions for improving the communication and self-regulation skills of children with ASD. Research has increasingly focused on the effectiveness of interventions for children with ASD. Nonetheless, research has yet remained an underappreciated concept in different cultural contexts. To address these gaps, the present study involved developing and testing the feasibility and effectiveness of the home-based Augmented Reality (AR) social story training modules for preschool children with ASD. The home-based AR social story training modules are designed. We recruited 15 children with ASD (3 to 5 years old). Wilcoxon signed rank test analysis was used to compare the differences in emotional functioning and adaptive behavior. Children received 8-week home-based AR training modules. Sessions were 20 minutes 4 times a week.
Patients receive letrozole PO QD for 2-8 weeks prior to surgery in the absence of disease progression or unacceptable toxicity. Patients then undergo collection of blood and tissue samples.
Participant allocated to the usual care arm will receive intravenous balanced crystalloid administered as the sole intravenous fluid during the initial 6 hour resuscitation period. The clinician can deliver up to 30ml/kg in the first 3 hours using 250ml boluses of balanced crystalloid based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). Thereafter, further crystalloid boluses up to 6 hours will be at the discretion of the clinical team and will be documented in the CRF. Patients in the balanced crystalloid arm should not receive albumin as a resuscitation fluid in the first 6 hours.
Although research has demonstrated the efficacy of various psychological and pharmacological treatments for irritable bowel syndrome (IBS)1, health professionals have limited information about how to determine which specific treatment regimens lead to optimal outcomes for specific IBS populations 2,3. A prevalent syndrome, with high healthcare costs, IBS is a debilitating chronic functional bowel disorder with increasingly interconnected psychosocial and gastrointestinal afflictions4. In general, IBS sufferers have not been found to respond consistently to a single medication or class of medications5. In the wake of the failures of medical therapies, many psychological interventions, adjunct to standard IBS treatments, have been examined1,6 such as Blanchard and Scharff's 2002 review of 12 random controlled trials that found strong evidence for the utility of hypnotherapy, cognitive behavioral therapy (CBT), and brief psychodynamic psychotherapy in helping to alleviate IBS symptoms7. Similarly, in a more recent study involving a meta-analysis of seventeen studies, with randomized trials comparing classes of psychological interventions, found that these psychological treatments also play a role in improving quality of life of IBS suffers1. Among these psychological interventions, cognitive behavioral therapy (CBT), a prescriptive therapy that specifically targets faulty thinking patterns, has been found to be quite effective in many empirical investigations. Recent evaluations of CBT interventions have found the therapy to have a direct effect on global improvements of IBS symptoms and quality of life8. Despite its demonstrated effectiveness, however, CBT does not work for all patients3,6,8. The successes of medical therapy alone compared to a treatment regimen combining psychological and pharmaceutical interventions have been greeted with mixed results- leading to the unnecessary waste of health resources in the course of treatment3,6. To decrease medical costs, as well to foster optimal treatment for IBS patients, there is a need for a better method of identifying which patients will most benefit from specific treatment options s (i.e. conventional medical treatment versus standard treatment and CBT)2,3.
PURPOSE: To prepare an inexpensive hybrid antiperspirant composition, comprising an active antiperspirant ingredient, a volatile silicone ingredient, a nonvolatile silicone ingredient, a suspending agent and water, having quick- drying properties without getting and good in touch. CONSTITUTION: This hybrid antiperspirant composition is prepared by mixing an active antiperspirant ingredient (e.g. an aluminum salt and an aluminum zirconium salt) with a volatile silicone ingredient (e.g. cyclomethicone), a nonvolatile silicone ingredient (e.g. dimethicone), a suspending agent and water. The content of the water based on the total weight of the composition is preferably 15-30wt.%, preferably 20-25wt.%. Aluminum chlorohydrate is cited as the aluminum salt and aluminum zirconium tetrachlorohydrex-Gly etc., are cited as aluminum zirconium salt.
PURPOSE:To provide an endometritis therapeutic drug which contains danazol as an active ingredient and which is vaginally or parenterally administered. CONSTITUTION:An endometritis therapeutic drug for being vaginally administered contains danazol: 17a-pregna-2,4-dien-20-yno[2,3d]-isoxasole-17-ol, in a dose of 0.5-20mg, preferably 1-10mg, as an active ingredient, and is prepared in the form of either of powder, tablets, suppositories, capsules and solutions. An endometritis therapeutic drug for being parenterally and non-vaginally administered comprises the danazol dissolved in a biocompatible solvent (e.g. lipidol) oily solution or a diluted ethyl alcohol aqueous solution) in a concentration of 50mg to 20g, preferably 200mg to 10g, per 100ml of the solvent. The parenteral and non-vaginal administration is carried out by a method in which the drug is injected from the opening of an uterus into an uterovaginal canal, a method in which the drug is injected with an abdominal cavity mirror or on a celiotomy operation, a method in which a posterior vaginal inner lid is needled and the drug is transvaginally injected through the needled part, etc. The administration methods are never accompanied by adverse actions such as the increase in body weights and the damages to hepatic functions.
Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a pathology with a very poor prognostic, the only curative treatment option being surgery, in association with chemotherapy. This study aims to assess the influence that the use of a standardized pathology report after a pancreaticoduodenectomy (PD) has on the R1 margins rate and the impact that this has on long term survival. Material and Methods: We included 116 patients admitted to the Regional Institute of Gastroenterology and Hepatology Prof. Dr. O. Fodor Cluj Napoca, who underwent PD for PDAC (Pancreatic Ductal Adenocarcinoma) between January 2012 and May 2017. We divided them in two groups: 59 patients for which a nonstandardized histopathological protocol was used and 57 patients for which a standardized protocol was implemented. We considered a margin to be R1 when there were tumor cells at ¤ 1 mm from the resection margin. Results: The R1 percentage in the first group of patients was of 39%, while the R1 resection rate in the second group was of 68.4%. The median survival rate was similar in the two groups, with no statistically significant difference between them, but in the prospective study when comparing R0 vs R1 margins there was a statistically differences in 5 year OS with a p-value = 0.03. Conclusion: The use of a standardized pathology report reveals a significant increase in R1 resection rates. Also study revealed not only increasing R1 incidence when using a standardized histopathology report, but also that those margins (R1) playing a determinant role in 5-year OS. The mesopancreas is the most frequently R1 resection margin.
PROBLEM TO BE SOLVED: To obtain the subject composition having a comfortable touch when applied to skin in spite of an oil-in-water type emulsion containing a wax in a high proportion by including a specific anionic emulsifying agent and a specified amount of the wax and converting an oily phase into the form of a soft paste at room temperature. SOLUTION: This composition is obtained by including (A) an anionic emulsifying agent which is a liquid at room temperature (15-25 deg.C) (e.g. oleyl phosphate, trioleyl phosphate or octadecyl phosphate) and (B) a wax (e.g. carnauba wax, a polyethylene wax having >=65 deg.C melting starting temperature or a microcrystalline wax having >=65 deg.C melting starting temperature) in an amount of >=5 wt.% based on the total amount of the composition and converting an oily phase into the form of a soft paste at room temperature. The ingredient A is preferably contained in an amount of 0.1-10 wt.% expressed in terms of an active substance and based on the total amount of the composition.  The oily phase is contained in an amount of 10-70 wt.% based on the total amount of the composition and the aqueous phase is contained in an amount of preferably >=30 wt.% based on the total amount of the composition.
PURPOSE: A sustained release liquid formulation containing enteric polymers and a method for manufacturing the same are provided to solidify the formulation in intestine and to prevent inactivated drug from gastric acid. CONSTITUTION: A sustained release liquid formulation contains lactic acid bacteria and carboxyl group-containing enteric polymers. The enteric polymers are dissolved in a medium. The medium is a pharmaceutically acceptable electrolytic solution of pH 6-9. The electrolyte is sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hydroxide, sodium pyrophosphate, potassium pyrophosphate, sodium phosphate, monobasic, ammonium hydrogen carbonate, potassium phosphate, sodium acetate, or a mixture thereof. The medium further contains cyclodextrin, casein, povidone, hydroxypropyl methyl cellulose(HPMC), diethyl phthalate(DEP), dimethyl phthalate(DMP), xylitol, inulin, amylase, chitosan, chondroitin sulfate, dextran, guar gum, pectin, or xylene. A method for preparing the liquid formulation comprises: a step of dissolving the enteric polymers in the electrolytic solution; and a step of dissolving or dispersing the lactic acid in the enteric polymer solution. [Reference numerals] (AA) Elution rate(%); (BB) Time(minutes)
The invention discloses traditional Chinese medicinal liquor for treating cold cough. The traditional Chinese medicinal liquor is prepared from medicinal materials including 30g of Folium Mori, 30g of Flos Chrysanthemi, 10g of Herba Menthae, 30g of Fructus Forsythiae, 30g of Semen Armeniacae, 30g of Radix Platycodonis and 10g of Radix Glycyrrhizae. The traditional Chinese medicinal liquor is prepared by grinding the medicinal materials, putting into a container, adding 1200ml of glutinous rice wine, and soaking for 10 days. The traditional Chinese medicinal liquor is supposed to be taken orally by 15-20ml each time in the morning and in the evening per day. The traditional Chinese medicinal liquor is reasonable in matching and extensive in material source and has efficacies of heat clearing, detoxifying, wind dispelling, heat dispersing, lung ventilating and cough arresting. Furthermore, the traditional Chinese medicinal liquor has advantages of low cost, quick action and excellent curative effects in treatment of slight thirst, nasal obstruction, cold cough, slight fever, evil ascending to upper warmer and initial stage of wind-cold caused diseases.
Many of the pathological consequences of chronic kidney disease can be attributed to an elevation in serum phosphate levels. Current therapies focused on decreasing intestinal phosphate absorption to treat hyperphosphatemia are inadequate. The most effective therapeutic strategy may be to target multiple absorptive pathways. In this study, the ability of a novel inhibitor of the intestinal sodium hydrogen exchanger 3 (NHE3), LY3304000, which inhibits paracellular, diffusional uptake of phosphate, to work in combination with an inhibitor of the active transporter, sodium dependent phosphate cotransporter 2b (NPT2b), LY3358966, was explored. LY3304000 modestly inhibited the acute uptake of phosphate into plasma of rats, while surprisingly, it doubled the rate of phosphate uptake in mice, an animal model dominated by NPT2b mediated acute phosphate uptake. In rats, LY3004000 and LY3358966 work in concert to inhibit acute phosphate uptake. On top of LY3358966, LY3304000 further decreased the acute uptake of phosphate into plasma. Studies measuring the recovery of radiolabeled phosphate in the intestine demonstrated LY3304000 and LY3358966 synergistically inhibited the absorption of phosphate in rats. We hypothesize the synergism is because the NHE3 inhibitor, LY3304000, has two opposing effects on intestinal phosphate absorption in rats, first it decreases diffusion mediated paracellular phosphate absorption, while second, it simultaneously increases phosphate absorption through the NPT2b pathway. NHE3 inhibition decreases proton export from enterocytes and raises the cell surface pH. In vitro, NPT2b mediated phosphate transport is increased at higher pHs. The increased NPT2b mediated transport induced by NHE3 inhibition is masked in rats which have relatively low levels of NPT2b mediated phosphate transport, by the more robust inhibition of diffusion mediated phosphate absorption. Thus, the inhibition of NPT2b mediated phosphate transport in rats in the presence of NHE3 inhibition has an effect that exceeds its effect in the absence of NHE3 inhibition, leading to the observed synergism on phosphate absorption between NPT2b and NHE3 inhibition.
A composition of vinegar and black seed mixed together. Black seed possess inherent natural ingredients that can cure any type of cancer, kill AIDS, bird flu viruses or any other viruses. Black seed can be processed in multiple ways to deal with cancer cells. When black seed's inherent ingredient are fed to the part of body that contains cancer it will kill the cancer cell and heal the body, in addition, it will give nutritional boost needed to improve immune system of the body. It will also make CD4 T cells clear of any virus attached to them. Also In general, black seed have ingredients to help cells to become healthy and kill cancerous cells in body. Black seed can be processed in various forms and can react with various solutions, acids, elements and compounds to kill cancer cells.  Ultimately black seeds are the cure for any kind of cancer when inherent ingredients present within it are utilized. In addition, there are multiple other benefits black seed provides to body. When it comes in contact with AIDS and bird flu viruses it will kill the viruses on contact, hence healing the body from all type of viruses. Black seed will have to be treated with catalytic that would bring out the inherent ingredients potential to perform.
FIELD: biotechnology, molecular biology, genetic engineering. SUBSTANCE: synthetic gene encoding protein gelonin is obtained. This nucleotide sequence SEQ 1D N1 is determined and given in the invention description. Method of producing involves the stage of selection of DNA fragment sequence, the stage of synthesis that includes the separation of DNA fragment for two overlapping sets of single-stranded fragments of oligonucleyides. Chemically synthesized oligonucleotides are taken among the group consisting of Btgel 1, Btgel 2 and gel 1-gel 39 followed by their purification and phosphorylation at 5'-end. Annealing of oligonucleotide strands in combination with DNA duplex formation results to the formation of the synthetic gene. Also, recombinant strain E. coli transformed by the expression vector that provides the expression of protein gelonin is obtained. Vector has DNA fragment showing the sequence SEQ ID NI ligated in Eco RI/Hind III-fragment split by vector 223-3. This recombinant technology ensures to obtain the rich and reproducing source of gelonin that is an immunotoxic agent used for treatment of tumors. EFFECT: improved method of producing, valuable antitumor properties of the end product. 5 cl, 5 dwg, 9 ex
Disclosed is a specific regulator of Ii protein expression or immunoregulatory function. Specifically disclosed are several forms of the specific regulator of Ii, including those which function through the formation of a duplex molecule with an RNA molecule encoding mammalian Ii protein to inhibit Ii protein synthesis at the translation level. This class includes copolymers comprised of nucleotide bases which hybridize specifically to the RNA molecule encoding mammalian Ii protein, and also expressible reverse gene constructs. In other aspects, the disclosure relates to MHC class II-positive antigen presenting cells containing a specific regulator of Ii expression. Such cells are useful, for example, in the display of autodeterminant peptides in association with MHC class II proteins. Compositions of the invention find application in methods for treating diseases, for example malignancies and autoimmune disorders, in a patient by enhancing immunological attack on undesired cells. An additional application is the isolation of autodeterminant peptides from a cell.
The aim of this study is to investigate the possible effect of SDN on PHN. The study population consists of patients with chronic pain after herpes zoster.

The study is a controlled double-blinded randomized study. The participants will be divided into two groups, group A, the intervention group, will receive SDN in the area of pain. Group B, the control group will receive a sham procedure. The procedure will take place at the out-patient clinic at Odense University Hospital. The plan is to include 40 patients (20 in each group).